Valuation: Ipsen S.A.

Market Cap 12.77B 14.67B 12.09B 10.98B 20.52B 1,405B 20.62B 144B 55.68B 714B 55.09B 53.87B 2,285B P/E 2026 *
13x
P/E 2027 * 13.3x
Enterprise Value 11.54B 13.24B 10.92B 9.92B 18.53B 1,268B 18.62B 130B 50.28B 645B 49.75B 48.65B 2,064B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.26x
Free-Float
40.65%
Yield 2026 *
0.99%
Yield 2027 * 0.98%
1 day-3.20%
1 week-3.76%
Current month-8.95%
1 month-0.78%
3 months+2.05%
6 months+0.37%
Current year+23.08%
1 week 44.75
Extreme 44.75
46.23
1 month 44.75
Extreme 44.75
49.15
Current year 34.34
Extreme 34.34
51.1
1 year 32.02
Extreme 32.02
51.1
3 years 25.11
Extreme 25.11
51.1
5 years 21.17
Extreme 21.17
51.1
10 years 9.1
Extreme 9.1
51.1
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
-3.20%-3.76% - - 15.01B
+1.28%+2.62%+51.61%+100.19% 1,014B
+1.10%+1.45%+52.49%+67.37% 644B
+0.58%+3.54%+19.57%+73.56% 464B
-0.36%+4.54%+38.71%+38.21% 354B
+1.52%+3.46%+20.13%+25.75% 265B
+2.41%+5.70%+9.06%+13.60% 253B
+0.91%-0.70%+38.25%+45.67% 203B
+2.48%-2.43%-24.40%-58.09% 186B
+2.17%+4.20%+34.41%+99.41% 183B
Average +0.51%+1.98%+26.65%+45.07% 396.31B
Weighted average by Cap. +0.19%+2.35%+35.35%+61.57%

Financials

2026 *2027 *
Net sales 4.54B 5.22B 4.3B 3.91B 7.3B 500B 7.33B 51.22B 19.8B 254B 19.6B 19.16B 813B 4.64B 5.32B 4.39B 3.99B 7.45B 510B 7.49B 52.27B 20.21B 259B 20B 19.55B 829B
Net income 1.01B 1.16B 957M 869M 1.62B 111B 1.63B 11.39B 4.41B 56.48B 4.36B 4.26B 181B 985M 1.13B 933M 847M 1.58B 108B 1.59B 11.11B 4.3B 55.06B 4.25B 4.16B 176B
Net Debt -1.24B -1.42B -1.17B -1.06B -1.99B -136B -2B -13.96B -5.4B -69.18B -5.34B -5.22B -221B -2.3B -2.64B -2.18B -1.98B -3.69B -253B -3.71B -25.92B -10.02B -128B -9.92B -9.7B -411B
Logo Ipsen S.A.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
17/09/26 $44.75 -3.20% 266
16/09/26 $46.23 +0.67% 408
14/09/26 $45.92 -1.25% 235
09/09/26 $46.50 +1.29% 215
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
155.80EUR
Average target price
166.07EUR
Spread / Average Target
+6.59%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!